China has become a pharma powerhouse, but local firms still face a steep climb toward financial stability and global growth.
China's pharma industry experiencing a boom but many companies still face a host of challenges.
Qilai Shen / Getty Images
China has emerged as a powerhouse of biotech innovation, but local firms still face a steep climb toward financial stability and global growth. Swissinfo spoke with three Chinese companies navigating these hurdles as they set their sights on Europe.
Generated with artificial intelligence.
This content was published on
China now has its own cutting-edge pharma industry, creating opportunities and competition for big pharma players.
Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market…
The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and…
Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms,…
A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own…
